GlycoBioSciences Says Skin Ointment Infringed 2 Patents

Law360, New York (November 26, 2012, 2:22 PM EST) -- A Canadian pharmaceutical company hit dermatology drugmaker Innocutis Holdings LLC with a patent infringement suit Sunday, claiming the company's Bionect skin irritation ointment violated two patents.

Ontario-based GlycoBioSciences Inc. says in Washington federal court that Innocutis and exclusive licensee DARA BioSciences Inc. have been willfully infringing two patents by making and selling Bionect, a hyaluronic acid sodium salt solution for treating wounds, burns and other irritations.

According to the suit, the two American companies have had full knowledge of Glyco's patents but have continued to sell...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.